National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Appendix 11: Human Paillomavirus." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
217
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

Table A11–2 Health Care Costs Associated with HPV Disease in Women and Men

 

% with Care

Cost per Unit

Units per Case

Form of Treatment

WOMEN

 

Genital warts, limited

 

minor physical discomfort

100%

$50

3

physician a

 

100%

$50

1

diagnostic a

Genital warts, limited but recurring

 

minor physical discomfort

50%

$50

4

physician a/year

2 recurrences per year for 10 years

50%

$50

1

diagnostic a

Genital warts, extensive

 

some physical discomfort

100%

$50

3

physician a

Genital warts, extensive and recurring

 

some physical discomfort

100%

$50

4

physician a/year

2 recurrences per year for 10 years

100%

$50

1

diagnostic a

Cervical dysplasia

 

treated precancerous condition

100%

$650

1

physician c plus diagnostic c

follow-up period

100%

$100

6

physician b

All Cancers: assume average 25-year lag from infection

Cervical cancer—carcinoma in situ

treatment phase

100%

$50

5

physician a

 

100%

$500

1

diagnostic c

100%

$1,000

1

ambulatory surgery

post-treatment phase (follow-up)

100%

$50

3

physician a/year

 

100%

$50

3

diagnostic a/year

Cervical cancer-locally invasive at diagnosis

treatment phase (surgery, radiation, chemotherapy)

100%

$100

2

physician b

 

100%

$500

2

diagnostic c

100%

$4,000

1

hospitalization

100%

$500

2

surgeons/anesthesiologist

100%

$5,000

1

radiation

follow-up

10%

$100

4

physician b/year

 

10%

$50

4

diagnostic a/year

Page
217
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)